Sorafenib for Patients With Extensive Keloids

NCT01425216 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

60

Enrollment

INDIV

Sponsor class

Stopped IND application was not approved by the US FDA - Project was never started

Conditions

Keloids

Interventions

DRUG: Sorafenib

Sponsor

Tirgan, Michael H., M.D.